SRP4647

Galectin-7 human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)

• Synonyme(s) : Gal-7, Galactein 7, Galectin7, HKL-14, PI7, p53-induced gene 1 protein
• Code UNSPSC : 12352202
• Nomenclature NACRES : NA.32

Propriétés

• Source biologique: human
• Produit recombinant: expressed in E. coli
• Essai: ≥98% (HPLC); ≥98% (SDS-PAGE)
• Forme: lyophilized
• Poids mol.: ~15.4 kDa
• Conditionnement: pkg of 50 μg
• Conditions de stockage: avoid repeated freeze/thaw cycles
• Impuretés: endotoxin, tested
• Numéro d'accès NCBI: P47929
• Numéro d'accès UniProt: P47929
• Conditions d'expédition: wet ice
• Température de stockage: −20°C
• Informations sur le gène: human ... LGALS7(3963)

Description

Description générale

LGALS7 (galectin-7) is from the galectin family of β-galactoside-binding proteins. It is mainly present in the stratified epithelia, hair follicles and thymic Hassall′s corpuscles. The protein localizes in the nucleus and cytoplasm, and exists as a homodimer. Recombinant Human Galectin-7 is a 15.4kDa protein consisting of 136 amino acid residues

Actions biochimiques/physiologiques

LGALS7 (galectin-7) helps in maintaining skin homeostasis, particularly after skin injury. It is also involved in keratinocyte proliferation and differentiation via JNK1 (c-Jun N-terminal kinase)-miR-203-p63 pathway. LGALS7 is a biomarker for skin condition and skin barrier disruption. In HeLa cells, it induces apoptosis most likely via JNK signaling. LGALS7 is downregulated in SV40-transformed cells and squamous cell carcinoma cells. Change in its activity/expression is associated with the progression of various epithelia-associated cancers. LGALS7 also helps in postmenstrual endometrial re-epithelialization.

Forme physique

Sterile filtered and Lyophilized without additives.

Reconstitution

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstitute in water to a concentration of 0.1-1.0 mg/mL. This solution can then be diluted into other aqueous buffers.